RB To Split OTC And Infant Nutrition As CEO Hits Reset Button
Executive Summary
Reckitt Benckiser's new CEO Laxman Narasimhan has unveiled a turnaround plan which will see the company's OTC drugs and dietary supplements housed in a separate business to its infant nutrition products. RB is investing £2bn to get back on track after a couple of difficult years.
You may also be interested in...
RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
RB Predicts 'Challenging' Rest Of Year For OTC Business
Reckitt Benckiser is expecting its OTC sales to be hit by a weak cold and flu season this year, as the social distancing measures introduced to quash the COVID-19 outbreak also disrupt the circulation of seasonal illnesses.
People On The Move: Appointments At RB, Angelini And Weleda
Reckitt hires P&G veteran to lead its transformation, while Italy's Angelini and Switzerland's Weleda have new country chiefs.